Dynavax Technologies is a commercial stage biopharmaceutical company focused on developing and commercializing vaccines. Co.'s primary marketed product, HEPLISAV-B® (Hepatitis B Vaccine (Recombinant), Adjuvanted), is approved by the United States Food and Drug Administration for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults approved in the United States. Co. also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Co. developed CpG 1018 to provide an increased vaccine immune response, as demonstrated in HEPLISAV-B.